Asia-Pacific Gene Therapy Market - 2025-2033

Asia-Pacific Gene Therapy Market Size - Industry Trends & Outlook

The Asia-Pacific gene therapy market size reached US$ 1.06 Billion in 2024 and is expected to reach US$ 14.59 Billion by 2033, growing at a CAGR of 34.1% during the forecast period 2025-2033.

Gene therapy is a cutting-edge treatment method that fixes or replaces faulty genes to help prevent or cure diseases.

The Asia-Pacific gene therapy market is witnessing rapid growth, fueled by rising investments in biotechnology, increasing prevalence of rare and genetic disorders, and supportive government initiatives across countries like China, Japan, and South Korea. Key trends include the growing adoption of CRISPR-based gene editing, expanding clinical trial pipelines, and strategic collaborations between biotech firms and academic institutions. However, high treatment costs and regulatory complexities remain major restraints. Opportunities lie in leveraging regional manufacturing capabilities and personalized medicine advancements to accelerate commercial rollout and improve patient access across the region.

Major economies like China, Japan, and India are playing pivotal roles in shaping the market’s trajectory. China leads in clinical trial activity and regulatory momentum, with recent approvals such as BBM-H901 for hemophilia B demonstrating its commitment to accelerating gene augmentation therapies.

Japan continues to set regulatory benchmarks with approvals like Roctavian for hemophilia A and significant investments in regenerative medicine under its expedited approval pathways.

Meanwhile, India is gaining traction with increased biotech funding, the growth of gene therapy research hubs, and the establishment of government-led initiatives to promote genomic medicine and local manufacturing.

The region’s focus on gene augmentation combined with strategic partnerships between local and global biotech firms, rising healthcare spending, and a large patient pool, positions Asia-Pacific as the fastest-growing and most dynamic gene therapy market in the world.

Asia-Pacific Gene Therapy Market Dynamics: Drivers & Restraints

Rising Funding and Investments by the Government and Companies for Gene Therapy Research are Expected to drive the Gene Therapy market

Rising funding and investments are expected to lead the market expansion. Governments are raising funds in setting up research centers, particularly gene therapy to treat a number of rare diseases as well as chronic diseases such as cancer, cardiovascular diseases, and others.

For instance, in April 2024, the President of India, Smt Droupadi Murmu, launched India’s first home-grown gene therapy for cancer at IIT Bombay. As this line of treatment, named “CAR-T cell therapy”, is accessible and affordable, it provides a new hope for the whole of humankind. She expressed confidence that it will be successful in giving new lives to countless patients.

Rising investments by companies to expand their businesses by launching their operations in different parts of the country are also expected to drive the market growth.

For instance, in February 2024, Miltenyi Biotec announced that it would launch its operations in India with its first office and invest in setting up the Miltenyi Innovation and Technology Center as the CGT Centre of Excellence (COE) in Hyderabad, India. This COE will be one of its first of its kind in India, where scientists, researchers, industry experts, and clinicians can get classroom-to-hands-on training on cell and gene therapy (CGT) approaches right from proof-of-concept to pre-clinical/clinical development and commercialization.

And also, on May 31, 2023 Laurus Labs announced that it has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crore.

High developmental and treatment costs

The high developmental and treatment costs of gene therapies are expected to hinder the gene therapy market growth. Despite potential health benefits, the high costs of cell and gene therapies are expected to reduce the adoption of these procedures. In developing countries in Asia-Pacific, it is difficult for many individuals to get treated using gene therapy.

Gene therapies often come with exorbitant price tags, typically ranging from USD 300,000 to USD 4 million per patient, depending on the specific treatment and condition being addressed. For instance, the gene therapy Zolgensma, which treats spinal muscular atrophy, is priced at approximately USD 2.1 million per patient. Such high costs pose significant challenges for healthcare providers, especially smaller employers and Medicaid programs, leading to increased insurance premiums and limiting access for many patients.

Asia-Pacific Gene Therapy Market Segment Analysis

The Asia-Pacific gene therapy market is segmented based on approach, vector type, technique, and application.

Technique:

The gene augmentation in the technique is expected to hold 42.3% of the Asia-Pacific gene therapy market

The gene augmentation segment is expected to hold a significant portion of the Asia-Pacific gene therapy market, driven by its growing use in treating inherited genetic disorders and the region’s rising investment in cutting-edge biotechnologies. Gene augmentation, which delivers functional copies of defective or missing genes, has seen accelerated development across Asia-Pacific.

For instance, in April 2025, Belief BioMed (BBM), in collaboration with Takeda China, recently received approval from the National Medical Products Administration (NMPA) for BBM-H901 (Dalnacogene Ponparvovec Injection). This gene augmentation therapy is designed for the treatment of adult patients with moderate to severe hemophilia B, highlighting the region's growing capabilities in advancing gene-based treatments for inherited disorders.

Asia-Pacific Gene Therapy Market Competitive Landscape

The top companies in the Asia-Pacific gene therapy market include Thermo Fisher Scientific Inc., Genepeutic Bio, Biosyngen, Wuxiapptec, Esco Aster, CytoMed Therapeutics, PHARMICELL Co., Ltd, AnGes MG, Inc, MediPost, Transcell Biologics, among others.

The Asia-Pacific gene therapy market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.